Mirvetuximab Soravtansine — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
A Study to Assess Adverse Events and Change in Disease Activity in Participants
Phase 2 · Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer |
ABBV AbbVie Inc. | Mirvetuximab Soravtansine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|